TherapeuticsMD Inc (NASDAQ:TXMD) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Wednesday.
According to Zacks, “TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida. “
Separately, Noble Financial restated a “buy” rating and set a $17.50 target price on shares of TherapeuticsMD in a report on Monday, July 11th.
Shares of TherapeuticsMD (NASDAQ:TXMD) opened at 6.71 on Wednesday. The stock’s market cap is $1.32 billion. TherapeuticsMD has a 12 month low of $5.18 and a 12 month high of $11.26. The firm has a 50-day moving average price of $6.73 and a 200-day moving average price of $7.68.
TherapeuticsMD (NASDAQ:TXMD) last posted its earnings results on Thursday, August 4th. The company reported ($0.11) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by $0.01. The company had revenue of $4.40 million for the quarter, compared to analyst estimates of $5.63 million. The company’s quarterly revenue was down 8.3% on a year-over-year basis. During the same quarter last year, the firm earned ($0.16) EPS. Equities analysts expect that TherapeuticsMD will post ($0.43) EPS for the current fiscal year.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a women’s healthcare product company. The Company’s segment is creating and commercializing products for women. It is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. Its drug candidates are created using its SYMBODA hormone technology, which enables the administration of hormones with high bioavailability alone or in combination.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.